1
Arterial and venous thromboembolic diseases are a clinical and economic burden worldwide.
2
Similarly, presence of a prothrombin gene mutation showed a higher risk for venous thromboembolic events.
3
Background: Heparins are widely prescribed for prevention and therapy of arterial and venous thromboembolic diseases.
4
Thus, in this large cohort, histologic diagnosis was an independent risk factor for venous thromboembolic events.
5
The risk of venous thromboembolic events is thought to be highest in patients with membranous nephropathy.
6
New therapeutic aspects might impact on the duration of anticoagulant therapy after a venous thromboembolic event.
7
Objective: To determine the incidence of venous thromboembolic disease in children of Chinese origin, and associated predisposing factors.
8
Conclusions: Significant differences in the clinical profile of venous thromboembolic-related outcomes were observed according to the site of cancer.
9
Primary membranous nephropathy is associated with increased risk of venous thromboembolic events, which are inversely correlated with serum albumin levels.
10
The primary safety measure was the incidence of a composite of venous thromboembolic recurrence, major haemorrhage or all-cause mortality within 30 days.
11
The venous thromboembolic event risk according to serum albumin was obtained from an inception cohort of 898 patients with primary membranous nephropathy.
12
The prophylaxis and therapy of such venous thromboembolic events (VTE) in oncology have so far been achieved with low-molecular-weight heparins.
13
To better understand the relationship between histologic diagnosis and the risk of venous thromboembolic events we evaluated patients in the Toronto Glomerulonephritis Registry.
14
Patients who had an initially negative investigation and were not anticoagulated were followed for 6 months for the occurrence of recurrent venous thromboembolic events.
15
Direct oral anticoagulants, anti-IIa or anti-Xa, are widely used in the treatment and prevention of venous thromboembolic disease as well as in nonvalvular atrial fibrillation.
16
Risk factors were evaluated by Cox proportional hazards for 53 image-confirmed venous thromboembolic events in 44 patients during a median follow-up of 63 months.
